LRRK2 and cancer: Accumulative evidence has shown that PD patients generally have relatively reduced risks of colon, rectal, colorectal, and lung cancer and increased risks of brain cancer and melanoma, while genetic LRRK2-G2019S PD carriers have increased cancer risk, particularly regarding brain, breast, colon, and blood cancers.